about
Intravenous immunoglobulin, pharmacogenomics, and Kawasaki diseaseHigh-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki DiseaseTwo new susceptibility loci for Kawasaki disease identified through genome-wide association analysis.Cross-fostering increases TH1/TH2 expression in a prenatal dexamethasone exposure rat model.Effects of melatonin on prenatal dexamethasone-induced epigenetic alterations in hippocampal morphology and reelin and glutamic acid decarboxylase 67 levels.A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease.Genetic polymorphisms in Kawasaki disease.ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population.A genetic polymorphism (rs17251221) in the calcium-sensing receptor gene (CASR) is associated with stone multiplicity in calcium nephrolithiasis.IL-31 associated with coronary artery lesion formation in Kawasaki diseaseComparison of the laboratory data between Kawasaki disease and enterovirus after intravenous immunoglobulin treatment.Gender-dependent effect of GSTM1 genotype on childhood asthma associated with prenatal tobacco smoke exposureAugmented TLR2 expression on monocytes in both human Kawasaki disease and a mouse model of coronary arteritisNon-Langerhans cell histiocytosis in a child with Kawasaki disease.A replication study for association of ITPKC and CASP3 two-locus analysis in IVIG unresponsiveness and coronary artery lesion in Kawasaki diseaseDifferent genetic associations of the IgE production among fetus, infancy and childhoodReplication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility.Close correlation between season of birth and the prevalence of bronchial asthma in a Taiwanese population.Single-nucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki diseaseGenetic variants of CD209 associated with Kawasaki disease susceptibility.FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease.Different implications of paternal and maternal atopy for perinatal IgE production and asthma development.Leukocyte Mitochondrial DNA Copy Number Is Associated with Chronic Obstructive Pulmonary DiseaseGene-Gene Associations with the Susceptibility of Kawasaki Disease and Coronary Artery Lesions.Lack of association between CLEC5A gene single-nucleotide polymorphisms and Kawasaki disease in Taiwanese children.Ethnic Kawasaki Disease Risk Associated with Blood Mercury and Cadmium in U.S. ChildrenEarly and late effects of prenatal corticosteroid treatment on the microRNA profiles of lung tissue in rats.Increased risk of atopic dermatitis in preschool children with kawasaki disease: a population-based study in taiwan.Risk factors for mortality of pediatric patients without underlying diseases.Kawasaki disease: an update on diagnosis and treatment.Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker.Preventing coronary artery lesions in Kawasaki disease.CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease.Etanercept treatment for children with refractory juvenile idiopathic arthritis.Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment.Coronary artery fistula associated with Kawasaki disease.Predictive factors of persistent infantile atopic dermatitis up to 6 years old in Taiwan: a prospective birth cohort study.Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.Melatonin in the regulation of liver steatosis following prenatal glucocorticoid exposure.Clinical aspects and genetic analysis of Taiwanese patients with the phenotype of hyper-immunoglobulin E recurrent infection syndromes (HIES).
P50
Q26865524-7B7092CF-407C-450F-92EF-A2663EFCF1F7Q28396984-F7D18D73-C234-4BAC-B114-7E35C7907B80Q29417067-43542478-F8D1-4004-A32E-669FACB1D1D9Q30422417-705755C7-C991-4201-B393-FE1FE6FD7DA4Q30900954-7AEF5482-BB8B-42C5-A429-5A507FE69774Q33403042-3536B4EC-C537-4CFF-8AB0-D33CDD8729FDQ33566136-5B8BB0A6-902E-42C6-8703-B2091660AF01Q33886535-87509AED-F76E-4463-96EE-0986BAB98B76Q34038091-F6614770-6CF3-4490-A18E-4974244B80C1Q34047318-6AE3DF73-B2E1-4AAC-A2E7-4D13D302EED7Q34207898-11072790-5A11-443B-A1B0-BF214C59D754Q34307420-C586B775-E5E5-4EEC-898A-D515659DC066Q34318350-6AB27A95-15C1-42A5-89BE-CD7EE7FF3408Q34525617-D09F8730-9441-4F31-9A57-907C06C041E4Q34874251-5AD02887-7708-4B9E-97D0-CC7712406E0AQ34925550-B631C496-7750-461C-A377-EC910B2F663EQ34983500-3CCB48FC-2767-4577-8264-7045F15CF72BQ35053535-D40FDB20-7A10-4B64-9562-F87380C97757Q35118611-608F23C7-EF03-44D0-B732-645AF27A2707Q35229960-57F54551-7E11-4ABB-AF3F-F1C4A9BBF436Q35673684-DCA6A924-0B23-4DDD-8092-5257660DEFCBQ35681368-22B20741-CEE2-4462-B4BA-7D7E70C39CBEQ35783477-FA31998C-DC71-4A28-962F-8EFD4DF6A558Q35855926-1A18E790-2FAD-4DC9-9DFA-977C2BCF9DE1Q35868581-D804828E-3D80-4DA6-8203-262F0C1FAD89Q36513183-A502663C-1961-4922-AF84-C1E91269C48DQ36639916-02E9E1C6-A0E0-4DC2-91CC-4D944B26E38DQ37166692-804BB582-CA68-42EB-A8D9-C1213069624FQ37850866-F887810A-C1C9-4BDD-8068-52D6088DC56BQ37986163-3872059A-353D-45DE-B135-24646226F178Q39247857-FF54E081-E1CF-4347-A3B9-31BB23AAC5B8Q39399053-3F9DD0DC-25D0-4179-AA27-133E90870B7EQ40173126-0A4E0B02-2850-4A82-892D-42B83EB723ADQ40326459-E3D90F38-11BB-4AA6-BB5B-C6745FA28C0EQ40362824-E7907AFB-F308-42E7-9C86-9EBE3669C166Q40396117-3674F9E4-7636-4019-BE4F-9E04F988C0ABQ41544172-E391978B-72D9-4738-AB9A-990585BCCC9DQ41546604-8886EAE8-78C9-4EE1-A277-0986EDEBCBA1Q42123455-68EF4D60-8212-4AEE-B3E3-4DCB769FA1DAQ42480620-588E6C4D-1F48-4B75-9598-22693947715A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ho-Chang Kuo
@ast
Ho-Chang Kuo
@en
Ho-Chang Kuo
@es
Ho-Chang Kuo
@nl
Ho-Chang Kuo
@sl
type
label
Ho-Chang Kuo
@ast
Ho-Chang Kuo
@en
Ho-Chang Kuo
@es
Ho-Chang Kuo
@nl
Ho-Chang Kuo
@sl
prefLabel
Ho-Chang Kuo
@ast
Ho-Chang Kuo
@en
Ho-Chang Kuo
@es
Ho-Chang Kuo
@nl
Ho-Chang Kuo
@sl
P106
P1153
9433506500
P31
P496
0000-0002-3295-2984